on BIOSYNEX (EPA:ALBIO)
BIOSYNEX: Number of Shares and Voting Rights as of February 28, 2025
BIOSYNEX, a French company specializing in health diagnostics, has published a statement regarding its share capital as of February 28, 2025. As of that date, the company's capital consists of 18,748,031 shares. These shares confer a total of 22,531,235 net voting rights. This report is in accordance with Article L.233-8 II of the French Commercial Code.
Founded in 2005, BIOSYNEX is recognized for its expertise in rapid testing, biotherapies, and molecular biology. Present in 95 countries, the group generated revenue of €101.4 million in 2024. Listed on Euronext Growth Paris, BIOSYNEX continues to innovate in the field of diagnostics.
R. H.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all BIOSYNEX news